SEC Form 4 · accession 0001493152-26-042794
FibroBiologics, Inc. · FBLG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hamid Khoja
Officer — Chief Scientific Officer
Period of report
Sep 15, 2026
Accepted (ET)
Sep 15, 2026 · 7:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001958777
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 15, 2026 | A | 298,508 | $1.675 | A | 301,571 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy)F2,F3 | $1.55 | Sep 15, 2026 | A | 298,508 | A | — | Sep 15, 2031 | Common Stock | 298,508 | 298,508 | D |
Explanation of responses
- F1On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering").
- F2Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675.
- F3The warrants are exercisable at any time until they expire.
Remarks
Exhibit 24 Power of Attorney